ArticleJCO oncology advances2025

ACR-368, a CHK1/2 Kinase Inhibitor, in Patients With Relapsed or Refractory Desmoplastic Small Round Cell Tumor: Phase I/II Trial Results.

Emily K Slotkin et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.